Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Chiesi Farmaceutici
Former United States Securities and Exchange Commission attorney
Briscoe and the securities litigation firm of
Taylor LLP are investigating the acquisition of Cornerstone
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating the acquisition of Cornerstone Therapeutics, Inc. (“Cornerstone”) (NasdaqCM: CRTX) by Chiesi Farmaceutici S.p.A for shareholders. Under the terms of the proposed acquisition, Cornerstone shareholders will only receive $9.50 in cash for each share owned. The transaction price is well below at least one analyst’s estimated value of $14.00 per share. If you are an affected investor, and you want to learn more about the lawsuit or join the action, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, via email at WBriscoe@TheBriscoeLawFirm.com or Zach Groover at Powers Taylor LLP, toll free (877) 728-9607 or via e-mail at email@example.com. There is no cost or fee to you. The investigation into the Cornerstone sale is focused on whether minority shareholders are receiving adequate compensation for their shares in the proposed deal, whether the transaction properly values Cornerstone stock, and whether Cornerstone’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Notably, at least one analyst with Yahoo! Finance estimates that the true inherent value of Cornerstone stock could be as high as $14.00 per share. The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters. Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.